Endoscopy 2020; 52(06): 474-482
DOI: 10.1055/a-1120-8498
Innovations and brief communications

A new 12-French plastic stent for unresectable distal malignant biliary obstruction

Pierre H. Deprez
1   Department of Gastroenterology. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
,
Tom G. Moreels
1   Department of Gastroenterology. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
,
Tarik Aouattah
1   Department of Gastroenterology. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
,
Hubert Piessevaux
1   Department of Gastroenterology. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
,
Enrique Pérez-Cuadrado-Robles
1   Department of Gastroenterology. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
2   Department of Gastroenterology. Hôpital Européen Georges-Pompidou, Paris, France
› Author Affiliations


Zoom Image

Abstract

Background Self-expanding metal stents (SEMSs) are recommended in unresectable distal malignant biliary obstruction. However, problems with dysfunction and migration of these stents are not negligible. We aimed to investigate the effectiveness and safety of a new 12-Fr plastic stent.

Methods In an observational, prospective study, all consecutive patients who underwent biliary stenting with the 12-Fr stent were considered (index group). Referent groups were a historical cohort, matched by sex, etiology, and metastatic status, including patients with 10-Fr plastic stents and with fully covered and uncovered SEMSs (FCSEMSs and UCSEMSs). Outcomes were stent patency, recurrent biliary obstruction (RBO), technical success, 30-day mortality and adverse events. A post-procedure examination of removed stents was done.

Results 72 patients (median age 66, range 32 – 94 years, 50 % men) were included (24 index, 48 referents). There were no differences in median stent patency time (P = 0.684). RBO was significantly lower with the 12-Fr compared with the 10-Fr profile stent (50 % vs. 81.3 %, P = 0.04), but no difference was found compared with the FCSEMSs (50 % vs. 43.8 %, P = 0.698). Technical success was 100 %, with no differences in 30-day mortality P = 0.105). The adverse events rate was 4.2 % for both groups (index n = 1, referents n = 2). Of 11 removed 12-Fr plastic stents suspected to be dysfunctional, 7 (64 %) were still patent.

Conclusions This new 12-Fr plastic stent could be an effective and cheaper alternative to SEMSs in distal malignant biliary obstruction.



Publication History

Received: 19 January 2020

Accepted: 24 January 2020

Article published online:
30 March 2020

© Georg Thieme Verlag KG
Stuttgart · New York

Crossref Cited-by logo
Article Citations